Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Elizabeth Kepl"'
Autor:
Marcos C. Miranda, Elizabeth Kepl, Mary Jane Navarro, Chengbo Chen, Max Johnson, Kaitlin R. Sprouse, Cameron Stewart, Anne Palser, Adian Valdez, Deleah Pettie, Claire Sydeman, Cassandra Ogohara, John C. Kraft, Minh Pham, Michael Murphy, Sam Wrenn, Brooke Fiala, Rashmi Ravichandran, Daniel Ellis, Lauren Carter, Davide Corti, Paul Kellam, Kelly Lee, Alexandra C. Walls, David Veesler, Neil P. King
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract We previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and
Externí odkaz:
https://doaj.org/article/649dcf2c588340c39547078121604655
Autor:
Lilit Grigoryan, Audrey Lee, Alexandra C. Walls, Lilin Lai, Benjamin Franco, Prabhu S. Arunachalam, Yupeng Feng, Wei Luo, Abigail Vanderheiden, Katharine Floyd, Samuel Wrenn, Deleah Pettie, Marcos C. Miranda, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Natalie Brunette, Michael Murphy, Brooke Fiala, Lauren Carter, Robert L. Coffman, David Novack, Harry Kleanthous, Derek T. O’Hagan, Robbert van der Most, Jason S. McLellan, Mehul Suthar, David Veesler, Neil P. King, Bali Pulendran
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-14 (2022)
Abstract Adjuvants enhance the magnitude and the durability of the immune response to vaccines. However, there is a paucity of comparative studies on the nature of the immune responses stimulated by leading adjuvant candidates. In this study, we comp
Externí odkaz:
https://doaj.org/article/2196e1d269574af6a71cb396be3fe2ca
Autor:
Anna Lacasta, Hyung Chan Kim, Elizabeth Kepl, Rachael Gachogo, Naomi Chege, Rose Ojuok, Charity Muriuki, Stephen Mwalimu, Gilad Touboul, Ariel Stiber, Elizabeth Jane Poole, Nicholas Ndiwa, Brooke Fiala, Neil P. King, Vishvanath Nene
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
Nanoparticle vaccines usually prime stronger immune responses than soluble antigens. Within this class of subunit vaccines, the recent development of computationally designed self-assembling two-component protein nanoparticle scaffolds provides a pow
Externí odkaz:
https://doaj.org/article/b5fc3e93405c4593aafdbf5866c380d4
Autor:
Daniel Ellis, Natalie Brunette, Katharine H. D. Crawford, Alexandra C. Walls, Minh N. Pham, Chengbo Chen, Karla-Luise Herpoldt, Brooke Fiala, Michael Murphy, Deleah Pettie, John C. Kraft, Keara D. Malone, Mary Jane Navarro, Cassandra Ogohara, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Maggie Ahlrichs, Max Johnson, Alyssa Blackstone, Lauren Carter, Tyler N. Starr, Allison J. Greaney, Kelly K. Lee, David Veesler, Jesse D. Bloom, Neil P. King
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The unprecedented global demand for SARS-CoV-2 vaccines has demonstrated the need for highly effective vaccine candidates that are thermostable and amenable to large-scale manufacturing. Nanoparticle immunogens presenting the receptor-binding domain
Externí odkaz:
https://doaj.org/article/ee4c16cc940d4a98bc65cf319a369f9a
Autor:
Prabhu S. Arunachalam, Yupeng Feng, Usama Ashraf, Mengyun Hu, Alexandra C. Walls, Venkata Viswanadh Edara, Veronika I. Zarnitsyna, Pyone Pyone Aye, Nadia Golden, Marcos C. Miranda, Kristyn W. M. Green, Breanna M. Threeton, Nicholas J. Maness, Brandon J. Beddingfield, Rudolf P. Bohm, Sarah E. Scheuermann, Kelly Goff, Jason Dufour, Kasi Russell-Lodrigue, Elizabeth Kepl, Brooke Fiala, Samuel Wrenn, Rashmi Ravichandran, Daniel Ellis, Lauren Carter, Kenneth Rogers, Lisa M. Shirreff, Douglas E. Ferrell, Nihar R. Deb Adhikary, Jane Fontenot, Holly L. Hammond, Matthew Frieman, Alba Grifoni, Alessandro Sette, Derek T. O’Hagan, Robbert Van Der Most, Rino Rappuoli, Francois Villinger, Harry Kleanthous, Jay Rappaport, Mehul S. Suthar, David Veesler, Taia T. Wang, Neil P. King, Bali Pulendran
Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from a study in nonhuman primates demonstrating durable protect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de44c1f8032ce1fce3f8616c9cfcd459
Autor:
Shankar Subramaniam, David Veesler, Lauren Carter, David Novack, Claire Sydeman, Jane Fontenot, Douglas E. Ferrell, Galit Alter, Robbert van der Most, Robert L. Coffman, Elizabeth Kepl, Mary Jane Navarro, Alexander G. White, Ching-Lin Hsieh, Kenneth S. Plante, Francois Villinger, Katharina Röltgen, Prabhu S. Arunachalam, Alexandra C. Walls, Jason S. McLellan, Lisa Shirreff, Rino Rappuoli, Sally Shin, Venkata Viswanadh Edara, Jessica A. Plante, Brooke Fiala, Stephanie Fischinger, Chunfeng Li, Caroline Atyeo, Matthew J. Gorman, Chad J. Roy, Scott D. Boyd, Bali Pulendran, Kasi E. Russell-Lodrigue, Skye Spencer, Xiaoying Shen, Shakti Gupta, Derek T. O'Hagan, Pyone P. Aye, Meera Trisal, Neil P. King, JoAnne L. Flynn, Nadia A. Golden, Marcos C. Miranda, Michael E. P. Murphy, John C. Kraft, Mehul S. Suthar, Lilin Lai, Jason Dufour, Rudolph Bohm, Deleah Pettie, Lara A. Doyle-Meyers, David C. Montefiori, Christopher Monjure, Kenneth A. Rogers, Samuel Wrenn, Harry Kleanthous, Nicholas J. Maness, Jay Rappaport, Alex Lee Zhu, Natalie Brunette
Publikováno v:
Nature. 594:253-258
The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain
Autor:
Alexandra C. Walls, Laura A. VanBlargan, Kai Wu, Angela Choi, Mary Jane Navarro, Diana Lee, Laura Avena, Daniela Montes Berrueta, Minh N. Pham, Sayda Elbashir, Marcos C. Miranda, Elizabeth Kepl, Max Johnson, Alyssa Blackstone, Kaitlin Sprouse, Brooke Fiala, Megan A. O’Connor, Natalie Brunette, Prabhu S. Arunachalam, Lisa Shirreff, Kenneth Rogers, Lauren Carter, Deborah H. Fuller, Francois Villinger, Bali Pulendran, Michael S. Diamond, Darin K. Edwards, Neil P. King, David Veesler
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses aga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b41db2620d879ef9b5d36cae1917cb60
https://doi.org/10.1101/2022.02.07.479468
https://doi.org/10.1101/2022.02.07.479468
Autor:
M. Alejandra Tortorici, Alexandra C. Walls, Anshu Joshi, Young-Jun Park, Rachel T. Eguia, Marcos C. Miranda, Elizabeth Kepl, Annie Dosey, Terry Stevens-Ayers, Michael J. Boeckh, Amalio Telenti, Antonio Lanzavecchia, Neil P. King, Davide Corti, Jesse D. Bloom, David Veesler
Publikováno v:
Cell. 185(13)
The isolation of CCoV-HuPn-2018 from a child respiratory swab indicates that more coronaviruses are spilling over to humans than previously appreciated. We determined the structures of the CCoV-HuPn-2018 spike glycoprotein trimer in two distinct conf
Autor:
Lilit Grigoryan, Audrey Lee, Alexandra C. Walls, Lilin Lai, Benjamin Franco, Prabhu S. Arunachalam, Yupeng Feng, Wei Luo, Abigail Vanderheiden, Katharine Floyd, Samuel Wrenn, Deleah Pettie, Marcos C. Miranda, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Natalie Brunette, Michael Murphy, Brooke Fiala, Lauren Carter, Robert L. Coffman, David Novack, Harry Kleanthous, Derek T. O’Hagan, Robbert van der Most, Jason S. McLellan, Mehul Suthar, David Veesler, Neil P. King, Bali Pulendran
Publikováno v:
NPJ vaccines. 7(1)
Adjuvants enhance the magnitude and the durability of the immune response to vaccines. However, there is a paucity of comparative studies on the nature of the immune responses stimulated by leading adjuvant candidates. In this study, we compared five
Autor:
Bali Pulendran, Allison J. Greaney, Max Johnson, Brooke Fiala, Ralph S. Baric, Jesse D. Bloom, Tyler N. Starr, Elizabeth Kepl, Rashmi Ravichandran, David Veesler, Roland Tisch, Mary-Jane Navarro, Kenneth A. Rogers, Kaitlin R. Sprouse, Kelly D. Smith, Natalie Brunette, Megan A. O'Connor, M. Alejandra Tortorici, Douglas E. Ferrell, Davide Corti, Prabhu S. Arunachalam, Timothy P. Sheahan, Samuel Wrenn, Robbert van der Most, Sarah R. Leist, Lisa Shirreff, Harry Kleanthous, Marcos C. Miranda, Alyssa Blackstone, Claire Sydeman, Francois Villinger, Jason S. McLellan, Deleah Pettie, David R. Martinez, Cassandra Ogohara, Minh N. Pham, Lauren Carter, Wesley C. Van Voorhis, Deborah H. Fuller, Samantha K Zepeda, Alexandra Schäfer, Sasha W Tilles, Matthew Clark, Alexandra C. Walls, Rino Rappuoli, John E. Bowen, Neil P. King, Derek T. O'Hagan, Ching-Lin Hsieh
Publikováno v:
Cell
bioRxiv
article-version (status) pre
article-version (number) 1
bioRxiv
article-version (status) pre
article-version (number) 1
Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is key for guiding public health policies. We show that a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine (RBD-NP)